AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03836248 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham osteopathic treatment
Description: 5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed.
Study NCT03836248 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Current practice Medication treatment
Description: Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
Study NCT03836248 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Current practice Medication treatment
Description: Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
Study NCT03836248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current practice Medication treatment
Description: Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
Study NCT03094429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaBen®
Description: 2000 mg/day or 1000 mg/day, twice daily
Study NCT00300456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: daily, 12 weeks, see Arm Description for dosage information
Study NCT00300456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for placebo information
Study NCT00728845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
Study NCT00728845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
Study NCT00728845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: 200 mg orally BID (total daily dose of 400 mg)
Study NCT00728845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Dose of 200 mg/m2 IV on day 1 of each cycle
Study NCT02667730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 500 mg four times daily for 7 days
Study NCT01291329 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intracoronary human umbilical WJ-MSC transfer
Description: intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
Study NCT03071224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] MNI-946
Description: Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.
Study NCT03071224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetapir
Description: Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.
Study NCT02146079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
Study NCT02667730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: naproxen 500mg twice daily for 7 days
Study NCT02667730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 100mg twice daily
Study NCT02667730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy only
Description: physiotherapy only (no drug)
Study NCT02667730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiotherapy only
Description: physiotherapy only (no drug)
Study NCT02146079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
Study NCT00879814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086 vaccine or control
Description: intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
Study NCT00879814 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rLP2086 vaccine or control
Description: intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
Study NCT02855411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm
Study NCT02191618 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: WEB
Description: The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
Study NCT00939627 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00939627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01047891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
Study NCT02040519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Filling out voiding diaries.
Study NCT03328429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Excision
Description: Bartholin gland will be excised
Study NCT03094429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg total, twice daily
Study NCT00876057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total abdominal hysterectomy
Description: Total abdominal hysterectomy
Study NCT00876057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtotal abdominal hysterectomy
Description: Subtotal abdominal hysterectomy
Study NCT00438555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and children group
Description: 3 months workshops of parents and children intervention, guided by dietician and phycologist
Study NCT00438555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent's group
Description: 3 months workshop of parents intervention, guided by dietician and phycologist
Study NCT02952755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155/DWC20156
Study NCT02952755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20162
Study NCT04226469 — intervention group
Intervention type: PROCEDURE
Intervention: Tooth movement
Description: The subject's canines will be retracted distally and crevicular fluid is collected
Study NCT02703129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
Study NCT04455009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fitness Drink Formula
Description: Single drink provided following baseline assessments
Study NCT04455009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fitness Drink Formula
Description: Single drink provided following baseline assessments
Study NCT01787994 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.
Study NCT01202851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Program
Description: 3 times a week, 60 minute sessions for 6 weeks.
Study NCT02855411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, twice daily (BID) for 12 weeks, capsule
Study NCT01281852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01281852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01281852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01281852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT00907881 — intervention group
Intervention type: DRUG
Intervention: Sulfonylurea
Description: The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
Study NCT01936285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days
Study NCT01936285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03328429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Marsupialization
Description: Bartholin gland will be marsupialised
Study NCT03779568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose adjustment of bupivacaine
Description: Spinal bupivacaine dose will be adjusted according to previous patient experience.
Study NCT02007785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP treatment protocol
Description: Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
Study NCT04460378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy with Focus on guided exposure
Study NCT01989546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
Study NCT00587821 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
Study NCT02955654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
Study NCT02955654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
Study NCT02955654 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress management training
Description: Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
Study NCT03869957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
Study NCT00190203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy and duraplasty
Description: Decompressive hemicraniectomy and duraplasty
Study NCT00190203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemicraniectomy
Description: hemicraniectomy
Study NCT04129684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: subgingival delivery and lozenges
Study NCT04129684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: subgingival delivery and lozenges
Study NCT04242017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptoreline
Description: Comparison of the duration of ADT (Triptoreline)
Study NCT04242017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptoreline
Description: Comparison of the duration of ADT (Triptoreline)
Study NCT04042610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Prompt for Interrupting Sitting Time
Description: An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
Study NCT01477697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: 50 mg/kg per day of omega-3 fatty acids
Study NCT01477697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg/kg per day of placebo equivalent
Study NCT03462446 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by treating physicians
Study NCT03462446 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonists (VKAs)
Description: As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
Study NCT00110656 — intervention group
Intervention type: OTHER
Intervention: Observations
Description: This is a non-interventional study- only observational.
Study NCT03614533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-Typhoid Conjugate Vaccine (Vi-TCV)
Description: Single 0.5-ml intramuscular injection
Study NCT03614533 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliovirus Vaccine (IPV)
Description: Single 0.5-ml intramuscular injection
Study NCT00784030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
Study NCT02360306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial Ultrasound
Description: Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
Study NCT02360306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound
Description: Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
Study NCT02106533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
Study NCT02415387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: typhoid vaccine
Description: Given IM
Study NCT02415387 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: typhoid vaccine
Description: Given IM
Study NCT02415387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IM
Study NCT02415387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IM
Study NCT00561171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPP635
Description: oral once daily
Study NCT04355299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balance training
Description: The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
Study NCT04355299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
Study NCT04355299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Aerobic exercise is any activity that gets your blood pumping and large muscle groups working. It's also known as cardiovascular activity.
Study NCT04355299 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual care
Description: received usual care
Study NCT05583682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental restoration
Description: Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material
Study NCT02672540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SANGUINATE 320 mg/kg
Description: Two-hour infusion of SANGUINATE on Day 1 and Day 2
Study NCT02672540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Two-hour infusion of Normal Saline and Day 1 and Day 2
Study NCT05476406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: äKwä skincare system products
Description: The skincare product system tested in this study was äKwä 6-step skincare system from 4Life Research USA, LLC ( https://www.4life.com/6613461/page/äKwä). Product directions state to use the following products morning and night in sequential order: First Wave Oil-to-Foam Cleanser, Glacier Glow Four-Way Toner, Precious Pool Vitamin Essence, Ripple Refine Eye Cream, and RainBurst Moisture Cream.
Study NCT05476406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: competitor products (control)
Description: Participants use whatever their normal daily routine of skincare products, which are commercially available competitor products from the marketplace.
Study NCT04085393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
Description: GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
Study NCT01984788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCX4161
Study NCT01984788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00944671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine (+) calcium carbonate (+) magnesium hydroxide tablet
Description: A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
Study NCT00944671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water
Description: A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
Study NCT00944671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water
Description: A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods